Saturday 17 October 2026
Export CBLL’s income statement to Excel — free account
CeriBell, Inc.
CBLL Healthcare Medical Devices
CeriBell, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $89.1 million, up 36.1% from fiscal 2024. In the quarter to June 2026, revenue grew 32.5%, EPS fell 34.2%, free cash flow fell 68.6% and total debt rose 1.52%, each against the same quarter a year earlier.
25.04
2.60
−9.41%
Follow CBLL
| Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|
Piotroski F-Score |
— | — | 4 |
P/E ratio |
0.00 | 0.00 | 0.00 |
Altman Z-Score |
— | 5.18 | 10.80 |
P/S ratio |
2.41 | 4.73 | 9.00 |
Altman Z″-Score (non-manufacturers) |
(7.73) | 8.21 | 3.97 |
P/FCF ratio |
0.00 | 0.00 | 0.00 |
Beneish M-Score |
— | (2.33) | (2.42) |
P/Operating CF |
(16.49) | (31.00) | (74.38) |
P/B ratio |
0.00 | 1.62 | 5.16 |
Price to Tangible BV |
0.00 | 1.62 | 5.16 |
EV/Sales |
2.50 | 2.05 | 7.43 |
EV/EBITDA |
0.00 | 0.00 | 0.00 |
EV/Operating CF |
(4.61) | (3.84) | (16.22) |
EV/FCF |
(4.47) | (3.67) | (15.64) |
Quick Ratio |
1.97 | 15.80 | 9.08 |
Current Ratio |
2.41 | 16.73 | 9.73 |
Net Debt/EBITDA |
1.20 | 4.58 | 2.38 |
Debt/Assets |
0.00% | 8.68% | 10.12% |
Debt/Equity |
0.00 | 0.10 | 0.13 |
Asset Turnover |
0.00 | 0.46 | 0.42 |
Operating CF/Net income |
0.99 | 0.87 | 0.76 |
Capex/Depreciation |
(1.46) | (1.05) | 5.97 |
Interest Coverage |
(14.32) | (19.93) | (30.90) |
| 0.00% | (102.53%) | (30.83%) | |
| 0.00% | (28.46%) | (25.36%) | |
ROIC |
0.00% | (151.76%) | (229.77%) |
Return on Tangible Assets |
(92.25%) | (19.58%) | (31.50%) |
Average Days of Receivables |
64.20 | 60.67 | 61.69 |
Research and Development Expense of Revenue |
19.89% | 20.72% | 21.49% |
Selling, General and Administrative Expense of Revenue |
130.92% | 126.67% | 131.97% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
5.92% | 8.27% | 13.72% |
Graham Net Nets |
(1.05) | 0.59 | 0.18 |
Graham Number |
0.00 | 0.00 | 0.00 |
Earnings Yield |
(25.36%) | (20.94%) | (6.70%) |
Free Cash Flow Yield |
(23.25%) | (11.85%) | (5.28%) |
Revenue per Share |
8.53 | 5.48 | 2.44 |
Operating CF per Share |
(5.50) | (2.93) | (1.12) |
Capex per Share |
(0.33) | (0.13) | (0.04) |
Free Cash Flow per Share |
(5.83) | (3.07) | (1.16) |
Cash per Share |
6.50 | 16.27 | 4.36 |
Shareholders Equity per Share |
(21.16) | 16.00 | 4.25 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 |
Book value per Share |
(21.16) | 16.00 | 4.25 |
Free Cash Flow |
(30.92) | (36.64) | (42.33) |
Working Capital |
30.36 | 204.28 | 167.53 |
Capital Expenditures |
(1.76) | (1.60) | (1.52) |
Net Current Asset Value |
(119.21) | 183.03 | 146.25 |
EV/EBIT |
0.00 | 0.00 | 0.00 |
Capex to Sales |
0.04 | 0.02 | 0.02 |
Price to Operating Income |
0.00 | 0.00 | 0.00 |
| Other line items | |||
Depreciation/Fixed assets |
0.77 | 0.66 | (0.13) |
Cash ROIC |
39.77% | (9.05%) | (12.66%) |
Accounts Receivable Turnover |
0.00 | 6.95 | 6.87 |
Accounts Payable Turnover |
0.00 | 9.27 | 5.42 |
Inventory Turnover |
0.00 | 1.36 | 1.52 |
Average Days of Payables |
37.83 | 47.99 | 96.01 |
Days of Inventory on Hand |
303.29 | 291.24 | 246.56 |
Average Receivables |
— | 9.42 | 12.97 |
Average Payables |
— | 0.94 | 1.99 |
Average Inventory |
— | 6.40 | 7.11 |
Average Assets |
— | 142.17 | 210.61 |
Average Common Equity |
— | 39.46 | 173.25 |
Columns are period end dates